The search for an endogenous psychotomimetic agent that might playa role in schizophrenia has failed for 40 years to show one. Previous candidates have included a-methylated derivatives of catecholamines, and N-and a-methylated derivatives of indolcalkylamines, which for various reasons failed the test. In 1954 Hoffer, Osmond and Smythies I reported that adrenochrome, the in vitro oxidation product of adrenaline, was psychotomimetic in humans. This was confirmed by three groups2-4 and denied by ones. The latter, however, used adrenochrome semicarbazone, a quite different compound, so its finding is not relevant. Other groups found it had effects in animal tests similar to those of standard hallucinogcns/:". But as no evidence could be produced that it ever occurred in the body, interest in it lapsed.
However, there is now clear evidence that close relatives of adrenochrome (namely noradrenochrome and dopaminochrome) occur in the brain. First, neuromelanin is a complex polymer made up mainly ofbenzothiazine units derived from 5-S-cysteinyldopamine and an indole derived from an aminochromc/r"! (dopaminochrome in the substantia nigra and noradrcnochrome in the locus coeruleus). Secondly, the enzyme prostaglandin H synthetase, during the initial stage of prostaglandin synthesis in the brain, co-oxidizes dopamine to dopaminochrome or its dihydroxy leuk isomer I2 , 13. These quinones are highly toxic to neuronsl" and bind covalently to DNA and to several enzymes and microtubular proteinl '.
Neuromelanin has for long been regarded as an uninteresting inert cellular pigment with no clear function. However recent interest has focused on its power to chelate heavy metals, in particular iron, and the hypothesis has been advanced that it normally plays a role in protecting the cell from heavy metal toxicity IS. The fact that it is made up in part of potentially toxic oxidation products of catecholamines now suggests that it may play an additional role in protecting the cell from these compounds. Some failure in this function might lead to the cellular damage now reported in the brains of schizophrenics, e.g. loss of spines on cortical pyramidal cell dendrites l 6 ,17 and, in particular, damage to catecholamine pathways!", Mattammal and co-workers I Thus toxic oxidative products of dopamine, if produced in the pigmented neurons of the substantia ni8Ta pars compacta, may playa role in the genesis of Parkinson's disease; and, if produced in the pigmented dopaminergic neurons that project via the mesolimbic tract, they may do so for schizophrenia. The latter disease could also be linked to the abnormal production of oxidation products of noradrenaline in the pigmented cells of the locus coeruleus. The adrenergic systems (CI-3) of the pons that project to the hypothalamus and nucleus accumbens might likewise be involved. However there are no reports of neuromelanin in these neurons. If there is indeed no neuromelanin in these neurons it is of interest why adrenaline in the brain is not autooxidized to its aminochrome (adrenochrome), or at least if it is, why this does not then form neuromelanin, whereas its close relatives noradrenaline and dopamine are auto-oxidized in the brain to their respective aminochromes and form neuromelanin.
These neurotoxic quinones are formed by auto-oxidation of catecholamines, of which a simplified account is as follows. The catecholamine (e.g. dopamine) forms its quinone (dopamine quinone). This cyclizes to form dopaminochrome (also a quinone) and its dihydroxy analogue-leukdopaminochrome. The final product is the indole (5,6-dihydroxyindole) which can also form a quinone. The brain has several lines of defence against these neurotoxic quinones. The first is ascorbate, which can reduce the quinone back to dopamine. Then the glutathione-cysteine system forms 5-cysteinyl dopamine from the quinone'? and takes it out of circulation to contribute eventually to neuromelanin formation. Also 0-methylation of the dihydroxy compounds (dopamine, leukdopaminochrome, 5,6-dihydroxyindole) can prevent quinone formation 20,21. One product of these reactions (5-OH-6-MeO indole carboxylic acid) has been detected in urinc/". The last line of defence is co-polymerization of the indoles with the benzothiazines derived from 5-cysteinyl dopamine to form neuromelanin.
There is also a link between this system and the transmethylation system, abnormalities in which have been implicated in the genesis of neuropsychiatric disorders in the form of a lowered level of transmethylation 22-24. Thus a failure of sufficient methylation could lead to the production of toxic quinone derivatives of dopamine and other catecholamines according to the cellular defence mechanism described above. The action of dopaminochrome in inactivating COMT would further exacerbate the situation. Levels of 5-S-cysteinyl-DOPA have been reported to be raised in the caudate in schizophrenia-i, which suggests a disturbance in this system which awaits clarification.
Clearly further research is needed/". (i) Do noradrenochrome and dopaminochrome (and related compounds) share the neurotoxic and psychotomimetic effects of adrenochrome? (ii) Are there any demonstrable abnormalities in neuromelanin synthesis, or in the prostaglandin H synthetase system, in schizophrenia? (iii) Does neuromelanin occur in adrenergic neurons in the brain, and if not, why not? (iv) What is the role of 5-cysteinyl dopamine in the neuron? (v) Are these cytotoxic aminochromes related to apoptosis? (vi) Vanyl mandelic acid, the O-methylated metabolite of dopamine, is a close chemical relative of potent anti-oxidants such as ferulic acid: perhaps it has an important anti-oxidant role itself?
